Celcuity's (CELC) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Celcuity's stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, while five other analysts have given it a "buy" rating.
• The company's shares have shown a modest uptick of 0.6%, with an average price target currently set at $56.50.
• Celcuity reported an earnings per share of ($1.04), falling short of the consensus estimate, as institutional investors increase their stake in the company.

Celcuity (NASDAQ:CELC - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other analysts have also recently issued reports about the company. Stifel Nicolaus initiated coverage on Celcuity in a research report on Tuesday, July 1st. They set a "buy" rating and a $30.00 price target on the stock. HC Wainwright raised their price target on Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Needham & Company LLC reissued a "buy" rating and issued a $70.00 price target on shares of Celcuity in a report on Friday, October 3rd. Guggenheim assumed coverage on Celcuity in a report on Monday, September 22nd. They issued a "buy" rating on the stock. Finally, Leerink Partners raised their target price on Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a research report on Monday, July 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Celcuity presently has an average rating of "Moderate Buy" and an average price target of $56.50.

Celcuity Stock Up 0.6%

NASDAQ:CELC traded up $0.28 on Wednesday, hitting $49.50. 937,936 shares of the stock were exchanged, compared to its average volume of 1,013,242. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The stock has a fifty day moving average of $50.88 and a 200-day moving average of $25.55. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $63.06.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, equities analysts expect that Celcuity will post -2.62 earnings per share for the current year.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares of the company's stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 15.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock valued at $74,000 after buying an additional 3,766 shares during the period. AlphaQuest LLC increased its holdings in shares of Celcuity by 176.3% during the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock worth $95,000 after acquiring an additional 4,522 shares during the last quarter. Focus Financial Network Inc. acquired a new position in shares of Celcuity during the 1st quarter worth approximately $108,000. Finally, Perkins Capital Management Inc. acquired a new position in shares of Celcuity during the 1st quarter worth approximately $115,000. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.